Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.
Eli Lilly and Company and Incyte Corporation have announced on Wednesday that new data from RA-BEACON – a pivotal phase 3 study…
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).